AGP Picks
View all

Today's News: Middle East
Provided by AGP

Today's News: Middle East: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Today's News: Middle East.

August 2026

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30
31

September 2026

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6
7 8 9 10 11 12 13
14 15 16 17 18 19 20
21 22 23 24 25 26 27
28 29 30

October 2026

Mo Tu We Th Fr Sa Su
1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 31

Press releases published on August 21, 2026

SK pharmteco nimmt an der CPHI teil und präsentiert dort seine multimodalen CDMO-Kompetenzen sowie seine globale Produktionsinfrastruktur
Aug. 21, 2026

SK pharmteco nimmt an der CPHI teil und präsentiert dort seine multimodalen CDMO-Kompetenzen sowie seine globale Produktionsinfrastruktur

Indeterminate GlobeNewswire
SK pharmteco participera au salon CPHI et présentera ses capacités de CDMO multimodales ainsi que son infrastructure mondiale de fabrication
Aug. 21, 2026

SK pharmteco participera au salon CPHI et présentera ses capacités de CDMO multimodales ainsi que son infrastructure mondiale de fabrication

Indeterminate GlobeNewswire
ConConAI Announces $CON Presale Milestone as Project Reports More Than 4M Tokens Sold
Aug. 21, 2026

ConConAI Announces $CON Presale Milestone as Project Reports More Than 4M Tokens Sold

Indeterminate GlobeNewswire
RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement
Aug. 21, 2026

RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement

Indeterminate GlobeNewswire
Milestone Pharmaceuticals Initiates Pivotal Phase 3 Trial of Etripamil Nasal Spray for Self-Administered Treatment of Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR)
Aug. 21, 2026

Milestone Pharmaceuticals Initiates Pivotal Phase 3 Trial of Etripamil Nasal Spray for Self-Administered Treatment of Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR)

Indeterminate GlobeNewswire
Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 million Private Placement
Aug. 21, 2026

Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 million Private Placement

Indeterminate GlobeNewswire
Foresight Evaluates Expansion into New Technology Markets, Including AI-Based Technologies, Cybersecurity and Data Centers
Aug. 21, 2026

Foresight Evaluates Expansion into New Technology Markets, Including AI-Based Technologies, Cybersecurity and Data Centers

Indeterminate GlobeNewswire
Newcore Gold Announces Appointment of Vice President, Projects and Annual Grant of Equity Incentive Awards
Aug. 21, 2026

Newcore Gold Announces Appointment of Vice President, Projects and Annual Grant of Equity Incentive Awards

Indeterminate GlobeNewswire
Goliath Reports Multiple Holes Up To 7.38 g/t AuEq Over 35.7 Meters, Including 19.51 g/t AuEq Over 8.32 Meters at the High-Grade Gold Surebet Discovery that Remains Open for Expansion, Golden Triangle, B.C.
Aug. 21, 2026

Goliath Reports Multiple Holes Up To 7.38 g/t AuEq Over 35.7 Meters, Including 19.51 g/t AuEq Over 8.32 Meters at the High-Grade Gold Surebet Discovery that Remains Open for Expansion, Golden Triangle, B.C.

Indeterminate GlobeNewswire
Predictive Discovery Limited: Results of General Meeting
Aug. 21, 2026

Predictive Discovery Limited: Results of General Meeting

Indeterminate GlobeNewswire
STARTRADER Launches XAUUSD247, Extending Gold CFD Access Across the Full Week
Aug. 21, 2026

STARTRADER Launches XAUUSD247, Extending Gold CFD Access Across the Full Week

Indeterminate GlobeNewswire
Aberdeen Sets AGM Date
Aug. 21, 2026

Aberdeen Sets AGM Date

Indeterminate GlobeNewswire

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Today's News: Middle East

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.